Moclobemide versus fluoxetine for a major depressive episode.
(1995) Psychopharmacology — Vol. 118, n° 2, p. 183-187 (1995)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 549.77 KB
Details
- Authors
- Abstract
- The efficacy and tolerability of moclobemide (300-600 mg daily) and fluoxetine (20-40 mg daily) were compared in a 6-week, double-blind study of 65 inpatients and 34 outpatients suffering from major depressive episodes (DSM III-R). No statistically significant differences between the two treatment groups were noted regarding efficacy (HDRS, CGI) or safety (adverse events, laboratory examination, vital signs). Moclobemide (300-600 mg daily) and fluoxetine (20-40 mg daily) would thus appear to be comparable both in antidepressant efficacy and tolerability. Doubling the low dosage in non-responders after 3 weeks resulted in a statistically significant improvement of CGI in the moclobemide group by comparison with the fluoxetine group at study end, suggesting that 600 mg moclobemide/day can still improve the patient's condition, while 40 mg fluoxetine/day does not. Sexual dysfunction was reported in two patients taking fluoxetine.
- Affiliations
Citations
Reynaert, C., Parent, M., Mirel, J., Janne, P., & Haazen, L. (1995). Moclobemide versus fluoxetine for a major depressive episode. Psychopharmacology, 118(2), 183-187. https://doi.org/10.1007/BF02245838 (Original work published 1995)